Calendar

Date TBD

RECRUITINGphase readoutNCT07400653: A Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D)

Sponsor: Pfizer. Phase: PHASE3. Conditions: Obesity, Overweight and/or Obesity, Overweight, Diabetes, Type 2, Type 2 Diabetes

full page →ctgov ↗

RECRUITINGphase readoutNCT07029711: A Study to Learn About Medicine Called Ritlecitinib in Children Aged Between 6 to 12 Years With Severe Alopecia Areata

Sponsor: Pfizer. Phase: PHASE3. Conditions: Severe Alopecia Areata

full page →ctgov ↗

ACTIVE_NOT_RECRUITINGphase readoutNCT07177209: Describing Treatment Patterns and Creating an Updated Treatment Flow in an Ulcerative Colitis Population

Sponsor: Pfizer. Phase: . Conditions: Ulcerative Colitis

full page →ctgov ↗

ACTIVE_NOT_RECRUITINGphase readoutNCT06476665: A Study to Learn About the Safety of BESPONSA Injection in Pediatric Patients With Acute Lymphocytic Leukemia.

Sponsor: Pfizer. Phase: . Conditions: Acute Lymphocytic Leukemia

full page →ctgov ↗

RECRUITINGphase readoutNCT04606446: Study of PF-07248144 in Advanced or Metastatic Solid Tumors

Sponsor: Pfizer. Phase: PHASE2. Conditions: Locally Advanced or Metastatic ER+ HER2- Breast Cancer, Locally Advanced or Metastatic Castration-resistant Prostate Cancer, Locally Advanced or Metastatic Non-small Cell Lung Cancer

full page →ctgov ↗

RECRUITINGphase readoutNCT06760208: A Study to Learn More About Prevenar 20 Once it is Out in the Korean Market

Sponsor: Pfizer. Phase: . Conditions: Pneumococcal Immunization, Safety

full page →ctgov ↗

ACTIVE_NOT_RECRUITINGphase readoutNCT06546800: SPECIAL INVESTIGATION FOR ABRYSVO IN INDIVIDUALS AGED 60 YEARS OR OLDER

Sponsor: Pfizer. Phase: . Conditions: Respiratory Syncytial Virus Infection

full page →ctgov ↗

RECRUITINGphase readoutNCT05748171: A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALL

Sponsor: Pfizer. Phase: PHASE2. Conditions: ACUTE LYMPHOBLASTIC LEUKEMIA

full page →ctgov ↗

COMPLETEDphase readoutNCT05399329: Study to Evaluate Real-world Effectiveness With Palbociclib Plus Endocrine Therapy as First-line/Second-line Treatment for HR+/HER2- Advanced Breast Cancer in Japan

Sponsor: Pfizer. Phase: . Conditions: Breast Cancer

full page →ctgov ↗

RECRUITINGphase readoutNCT06866405: A Phase 3 Study of Revaccination in Subsequent Pregnancies With Bivalent RSV Vaccine and Duration of Protection of a Single Dose

Sponsor: Pfizer. Phase: PHASE3. Conditions: RSV Infection

full page →ctgov ↗

ACTIVE_NOT_RECRUITINGphase readoutNCT05909397: Vepdegestrant (ARV-471/PF-07850327) + Palbociclib vs Letrozole + Palbociclib in ER(+)/HER2(-) Advanced Breast Cancer

Sponsor: Pfizer. Phase: PHASE3. Conditions: Breast Cancer

full page →ctgov ↗

ACTIVE_NOT_RECRUITINGphase readoutNCT06973720: A Phase 2b Study to Evaluate the Efficacy and Safety of Once-Monthly MET097 in Adults With Obesity or Overweight

Sponsor: Metsera, a wholly owned subsidiary of Pfizer. Phase: PHASE2. Conditions: Obesity, Overweight or Obesity

full page →ctgov ↗

NOT_YET_RECRUITINGphase readoutNCT07597928: A Study to Learn How Different Forms of the Study Medicine Called PF-08049820 Are Absorbed and Eliminated in Healthy Adults

Sponsor: Pfizer. Phase: PHASE1. Conditions: Healthy Adults, Healthy

full page →ctgov ↗

RECRUITINGphase readoutNCT07426757: An Open-Label Study to Evaluate PF-07994525 in Participants With Advanced Cancers

Sponsor: Pfizer. Phase: PHASE1. Conditions: Advanced Malignancies, Advanced Cancer

full page →ctgov ↗

ACTIVE_NOT_RECRUITINGphase readoutNCT06965465: A Study to Learn How Different Amounts of the Study Medicine Called PF-07999415 Are Tolerated and Act in the Body in Healthy Adults

Sponsor: Pfizer. Phase: PHASE1. Conditions: Healthy

full page →ctgov ↗

TERMINATEDphase readoutNCT05983133: A Study of PF-08046052/SGN-EGFRd2 in Advanced Solid Tumors

Sponsor: Seagen, a wholly owned subsidiary of Pfizer. Phase: PHASE1. Conditions: Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Squamous Cell Carcinoma of the Head and Neck, Pancreatic Ductal Adenocarcinoma

full page →ctgov ↗

RECRUITINGphase readoutNCT07470879: A Study of How the Medicine Called "Etrasimod" Works in Children With the Gut Disease Called Ulcerative Colitis

Sponsor: Pfizer. Phase: PHASE2. Conditions: Colitis, Ulcerative

full page →ctgov ↗

COMPLETEDphase readoutNCT05709158: A Study to Learn About the Dangers Linked to Myelosuppression (Decreased Bone Marrow Function) in Breast Cancer Patients Treated With the Study Medicine Palbociclib (Pal Bow Sai Klib)

Sponsor: Pfizer. Phase: . Conditions: Breast Cancer

full page →ctgov ↗

WITHDRAWNphase readoutNCT06103734: A Study to Learn About Zavegepant as a Treatment for Multiple Migraine Attacks in Adult Participants

Sponsor: Pfizer. Phase: PHASE3. Conditions: Migraine

full page →ctgov ↗

RECRUITINGphase readoutNCT05431088: A Phase 2/3 Study in Adult and Adolescent Participants With SCD

Sponsor: Pfizer. Phase: PHASE2. Conditions: Sickle Cell Disease

full page →ctgov ↗

COMPLETEDphase readoutNCT04498481: TREATMENT AND MONITORING PATTERNS AND CLINICAL OUTCOMES IN PATIENTS RECEIVING PALBOCICLIB COMBINATION TREATMENT (WITH AI OR FULVESTRANT) FOR HR+/HER2- A/MBC IN A COMMUNITY ONCOLOGY SETTING.

Sponsor: Pfizer. Phase: . Conditions: Breast Cancer

full page →ctgov ↗

RECRUITINGphase readoutNCT07542886: A Study to Learn How Different Injector Pens Affect the Study Medicine Called Genotropin (Somatropin) Delivery and Taken up Into the Blood in Healthy Adults

Sponsor: Pfizer. Phase: PHASE1. Conditions: Healthy

full page →ctgov ↗

TERMINATEDphase readoutNCT06704724: A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.

Sponsor: Pfizer. Phase: PHASE1. Conditions: Carcinoma, Pancreatic Ductal, Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung

full page →ctgov ↗

RECRUITINGphase readoutNCT05689151: A Study to Learn About Abrocitinib in Adult Patients With Moderate to Severe Atopic Dermatitis.

Sponsor: Pfizer. Phase: . Conditions: Atopic Dermatitis, Eczema

full page →ctgov ↗

COMPLETEDphase readoutNCT01500551: Long-Term Safety Study Of Tofacitinib In Patients With Juvenile Idiopathic Arthritis

Sponsor: Pfizer. Phase: PHASE2. Conditions: Juvenile Idiopathic Arthritis

full page →ctgov ↗

COMPLETEDphase readoutNCT05228470: A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma.

Sponsor: Pfizer. Phase: PHASE2. Conditions: Elranatamab, Myeloma, Multiple Myeloma, Relapsed Multiple Myeloma, Refractory Multiple Myeloma, PF-06863135, BCMA, Bispecific, Bispecific Antibody, BCMA-CD3 Bispecific, MagnetisMM-8

full page →ctgov ↗

ACTIVE_NOT_RECRUITINGphase readoutNCT06613984: Korean Post Marketing Surveillance for Comirnaty Injection (Bretovameran)

Sponsor: Pfizer. Phase: . Conditions: COVID-19 Vaccination

full page →ctgov ↗

ACTIVE_NOT_RECRUITINGphase readoutNCT06651073: ATTR-CM: A Multi-country, Non-interventional Disease Registry

Sponsor: Pfizer. Phase: . Conditions: Transthyretin Amyloid Cardiopathy

full page →ctgov ↗

ACTIVE_NOT_RECRUITINGphase readoutNCT06447662: A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.

Sponsor: Pfizer. Phase: PHASE1. Conditions: Carcinoma, Pancreatic Ductal, Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung

full page →ctgov ↗

RECRUITINGphase readoutNCT06629779: A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.

Sponsor: Pfizer. Phase: PHASE3. Conditions: Metastatic Castration-Resistant Prostate Cancer

full page →ctgov ↗

RECRUITINGphase readoutNCT06899204: Real World Efficiency of Abrocitinib Treatment at Patients With Moderate to Severe Atopic Dermatitis Who Had Inadequate Response to Previous Biologic Therapies.

Sponsor: Pfizer. Phase: . Conditions: Atopic Dermatitis, Atopic Dermatitis, Unspecified, Dermatitis, Atopic

full page →ctgov ↗

RECRUITINGphase readoutNCT05020236: A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments

Sponsor: Pfizer. Phase: PHASE3. Conditions: Multiple Myeloma

full page →ctgov ↗

ACTIVE_NOT_RECRUITINGphase readoutNCT07249320: Evaluating ABRYSVO Maternal Vaccine Effectiveness Among Infants

Sponsor: Pfizer. Phase: . Conditions: Respiratory Syncytial Virus (RSV)

full page →ctgov ↗

COMPLETEDphase readoutNCT07423286: A Study to Understand What the Body Does to the Study Medicine Called PF-07248144 When Taken by Healthy Adults

Sponsor: Pfizer. Phase: PHASE1. Conditions: Healthy Adult Participants

full page →ctgov ↗

COMPLETEDphase readoutNCT06267963: A Study to Understand What the Body Does to the Study Medicine Called PF-07220060 When Taken by Healthy Adults

Sponsor: Pfizer. Phase: PHASE1. Conditions: Healthy Participants

full page →ctgov ↗

NOT_YET_RECRUITINGphase readoutNCT07772921: A Study to Learn About the Study Medicine Called Tilrekimig in People With Severe Asthma

Sponsor: Pfizer. Phase: PHASE3. Conditions: Asthma

full page →ctgov ↗

ACTIVE_NOT_RECRUITINGphase readoutNCT03950232: An Extension Study for Treatment of Moderately to Severely Active Ulcerative Colitis

Sponsor: Pfizer. Phase: PHASE3. Conditions: Ulcerative Colitis

full page →ctgov ↗

Week of Jul 27, 2026

Week of Aug 3, 2026

Week of Nov 2, 2026

Date TBD